Atossa Genetics (ATOS) had its price target raised by HC Wainwright from $7.00 to $25.00. They now have a "buy" rating on the stock.
Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22 [Seeking Alpha]
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives